11β-HSD1 inhibition ameliorates diabetes-induced cardiomyocyte hypertrophy and cardiac fibrosis through modulation of EGFR activity
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1363 views | HTML 2192 views | ?
Chunpeng Zou1,2,*, Weixin Li1,*, Yong Pan1,3,*, Zia A. Khan4, Jieli Li1, Xixi Wu1, Yi Wang1, Liancheng Deng1, Guang Liang1,3 and Yunjie Zhao1,3
1Chemical Biology Research Center, School of Pharmaceutical Science, Wenzhou Medical University, Wenzhou, Zhejiang, China
2Department of Ultrasonography, The Second Affiliated Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
3Affiliated Yueqing Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China
4Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada
*These authors have contributed equally to this work
Guang Liang, email: [email protected]
Yunjie Zhao, email: [email protected]
Keywords: diabetic cardiomyopathy; 11beta-HSD; glucocorticoids; fibrosis; EGFR
Received: July 17, 2017 Accepted: September 20, 2017 Published: October 24, 2017
11β-HSD1 has been recognized as a potential therapeutic target for type 2 diabetes. Recent studies have shown that hyperglycemia leads to activation of 11β-HSD1, increasing the intracellular glucocorticoid levels. Excess glucocorticoids may lead to the clinical manifestations of cardiac injury. Therefore, the aim of this study is to investigate whether 11β-HSD1 activation contributes to the development of diabetic cardiomyopathy. To investigate the role of 11β-HSD1, we administered a selective 11β-HSD1 inhibitor in type 1 and type 2 murine models of diabetes and in cultured cardiomyocytes. Our results show that diabetes increases cortisone levels in heart tissues. 11β-HSD1 inhibitor decreased cortisone levels and ameliorated all structural and functional features of diabetic cardiomyopathy including fibrosis and hypertrophy. We also show that high levels of glucose caused cardiomyocyte hypertrophy and increased matrix protein deposition in culture. Importantly, inhibition of 11β-HSD1 attenuated these changes. Moreover, we show that 11β-HSD1 activation mediates these changes through modulating EGFR phosphorylation and activity. Our findings demonstrate that 11β-HSD1 contributes to the development of diabetic cardiomyopathy through activation of glucocorticoid and EGFR signaling pathway. These results suggest that inhibition of 11β-HSD1 might be a therapeutic strategy for diabetic cardiomyopathy, which is independent of its effects on glucose homeostasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.